Sesen reports Phase III data for bladder cancer candidate Vicinium

Sesen Bio Inc. (NASDAQ:SESN) (formerly Eleven Biotherapeutics Inc.) said Vicinium (VB4-845) led to a complete response rate of 42% at three months in 77 evaluable

Read the full 256 word article

User Sign In